Surrozen, Inc./DE — Director's Dealing 2024

Apr 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Surrozen, Inc./DE (SRZN)
CIK: 0001824893
Period of Report: 2024-04-04

Reporting Person: COLUMN GROUP III GP, LP (N/A)
Reporting Person: COLUMN GROUP III-A, LP (N/A)
Reporting Person: COLUMN GROUP III, LP (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-04	Common Stock	P	90897	$15.50	Acquired	294767	Indirect
2024-04-04	Common Stock	P	102651	$15.50	Acquired	332885	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-04	Series A Common Warrants	$15.50	P	90897	Acquired		Common Stock (90897)	Indirect
2024-04-04	Series A Common Warrants	$15.50	P	102651	Acquired		Common Stock (102651)	Indirect
2024-04-04	Series B Common Warrants	$14.25	P	98870	Acquired		Common Stock (98870)	Indirect
2024-04-04	Series B Common Warrants	$14.25	P	111656	Acquired		Common Stock (111656)	Indirect
2024-04-04	Series C Common Warrants	$16.00	P	352225	Acquired		Common Stock (352225)	Indirect
2024-04-04	Series C Common Warrants	$16.00	P	397773	Acquired		Common Stock (397773)	Indirect
2024-04-04	Series D Common Warrants	$16.00	P	352225	Acquired		Common Stock (352225)	Indirect
2024-04-04	Series D Common Warrants	$16.00	P	397773	Acquired		Common Stock (397773)	Indirect

Footnotes

F1: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F3: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F4: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F5: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F6: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F7: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).